Tags

Type your tag names separated by a space and hit enter

The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.
Neurogastroenterol Motil. 2016 Dec; 28(12):1765-1780.NM

Abstract

BACKGROUND

In ancient medicine, extracts of the marijuana plant Cannabis sativa were used against diseases of the gastrointestinal (GI) tract. Today, our knowledge of the ingredients of the Cannabis plant has remarkably advanced enabling us to use a variety of herbal and synthetic cannabinoid (CB) compounds to study the endocannabinoid system (ECS), a physiologic entity that controls tissue homeostasis with the help of endogenously produced CBs and their receptors. After many anecdotal reports suggested beneficial effects of Cannabis in GI disorders, it was not surprising to discover that the GI tract accommodates and expresses all the components of the ECS. Cannabinoid receptors and their endogenous ligands, the endocannabinoids, participate in the regulation of GI motility, secretion, and the maintenance of the epithelial barrier integrity. In addition, other receptors, such as the transient receptor potential cation channel subfamily V member 1 (TRPV1), the peroxisome proliferator-activated receptor alpha (PPARα) and the G-protein coupled receptor 55 (GPR55), are important participants in the actions of CBs in the gut and critically determine the course of bowel inflammation and colon cancer.

PURPOSE

The following review summarizes important and recent findings on the role of CB receptors and their ligands in the GI tract with emphasis on GI disorders, such as irritable bowel syndrome, inflammatory bowel disease, and colon cancer.

Authors+Show Affiliations

Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.Department of Medicine, Ludwig-Maximilians University, Munich, Germany. Zentrum für Endoskopie, Starnberg, Germany.Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27561826

Citation

Hasenoehrl, C, et al. "The Gastrointestinal Tract - a Central Organ of Cannabinoid Signaling in Health and Disease." Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society, vol. 28, no. 12, 2016, pp. 1765-1780.
Hasenoehrl C, Taschler U, Storr M, et al. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil. 2016;28(12):1765-1780.
Hasenoehrl, C., Taschler, U., Storr, M., & Schicho, R. (2016). The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society, 28(12), 1765-1780. https://doi.org/10.1111/nmo.12931
Hasenoehrl C, et al. The Gastrointestinal Tract - a Central Organ of Cannabinoid Signaling in Health and Disease. Neurogastroenterol Motil. 2016;28(12):1765-1780. PubMed PMID: 27561826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. AU - Hasenoehrl,C, AU - Taschler,U, AU - Storr,M, AU - Schicho,R, Y1 - 2016/08/26/ PY - 2016/05/15/received PY - 2016/08/01/accepted PY - 2016/8/27/pubmed PY - 2018/2/1/medline PY - 2016/8/27/entrez KW - IBD KW - IBS KW - GPR55 KW - cannabinoid receptors KW - cannabis KW - colon cancer SP - 1765 EP - 1780 JF - Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society JO - Neurogastroenterol. Motil. VL - 28 IS - 12 N2 - BACKGROUND: In ancient medicine, extracts of the marijuana plant Cannabis sativa were used against diseases of the gastrointestinal (GI) tract. Today, our knowledge of the ingredients of the Cannabis plant has remarkably advanced enabling us to use a variety of herbal and synthetic cannabinoid (CB) compounds to study the endocannabinoid system (ECS), a physiologic entity that controls tissue homeostasis with the help of endogenously produced CBs and their receptors. After many anecdotal reports suggested beneficial effects of Cannabis in GI disorders, it was not surprising to discover that the GI tract accommodates and expresses all the components of the ECS. Cannabinoid receptors and their endogenous ligands, the endocannabinoids, participate in the regulation of GI motility, secretion, and the maintenance of the epithelial barrier integrity. In addition, other receptors, such as the transient receptor potential cation channel subfamily V member 1 (TRPV1), the peroxisome proliferator-activated receptor alpha (PPARα) and the G-protein coupled receptor 55 (GPR55), are important participants in the actions of CBs in the gut and critically determine the course of bowel inflammation and colon cancer. PURPOSE: The following review summarizes important and recent findings on the role of CB receptors and their ligands in the GI tract with emphasis on GI disorders, such as irritable bowel syndrome, inflammatory bowel disease, and colon cancer. SN - 1365-2982 UR - https://www.unboundmedicine.com/medline/citation/27561826/The_gastrointestinal_tract___a_central_organ_of_cannabinoid_signaling_in_health_and_disease_ L2 - https://doi.org/10.1111/nmo.12931 DB - PRIME DP - Unbound Medicine ER -